(19) 대한민국특허청(KR) (12) 공개특허공보(A) - Questel

공개특허 10-2011-0091780
MRA in rheumatoid arthritis. Phase I/II clinical study, J Rheumatol., 2003 Jul;30(7):1426-35; Mihara
M, et al, Humanized antibody to human interleukin-6 receptor inhibits the development of collagen
arthritis in cynomolgus monkeys, Clin Immunol., 2001 Mar;98(3):319-26; Nishimoto N, et al, Anti-
interleukin 6 receptor antibody treatment in rheumatic disease, Ann Rheum Dis., 2000 Nov;59 Suppl
1:i21-7; Tackey E, et al, Rationale for interleukin-6 blockade in systemic lupus erythematosus, Lupus,
200413(5):339-43; Finck BK, et al, Interleukin 6 promotes murine lupus in NZB/NZW Fl mice, J Clin
Invest., 1994 Aug;94 (2):585-91; Kitani A, et al, Autostimulatory effects of IL-6 on excessive B cell
differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R
expression, Clin Exp Immunol., 1992 Apr;88(1):75-83; Stuart RA, et al, Elevated serum interleukin-6
levels associated with active disease in systemic connective tissue disorders, Clin Exp Rheumatol.,
1995 Jan-Feb;l3 (1):17-22; Mihara M, et al, IL-6 receptor blockage inhibits the onset of autoimmune
kidney disease in NZB/W Fl mice, Clin Exp Immunol., 1998 Jun;12(3):397-402; Woo P, et al, Open label
phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile
idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of
arthritis and demonstration of prolonged clinical improvement, Arthritis Res Ther., 2005;7(6):RI281-8.
Epub 2005 Sep 15; Yokota S, et al, Clinical study of tocilizumab in children with systemic-onset
juvenile idiopathic arthritis, Clin Rev Allergy Immunol., 2005 Jun;28(3):231-8; Yokota S, et al,
Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with
systemic-onset juvenile idiopathic arthritis, Arthritis Rheum., 2005 Mar;52(3):818-25; de Benedetti F,
et al, Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic
arthritis?, Arthritis Rheum., 2005 Mar;52(3):687-93; De Benedetti F, et al, Is systemic juvenile
rheumatoid arthritis an interleukin 6 mediated disease?, J Rheumatol., 1998 Feb;25(2):203-7; Ishihara
K, et al, IL-6 in autoimmune disease and chronic inflammatory proliferative disease, Cytokine Growth
Factor Rev., 2002 Aug-Oct;13 (4-5):357- 68; Gilhar A, et al, In vivo effects of cytokines on psoriatic
skin grafted on nude mice :involvement of the tumor necrosis factor (TNF) receptor, Clin Exp Immunol.,
1996 Oct;106(1):134-42; Spadaro A, et al, Interleukin-6 and soluble interleukin-2 receptor in
psoriatic arthritis: correlations with clinical and laboratory parameters, Clin Exp Rheumatol., 1996
Jul-Aug;14 (4):413-6; Ameglio F, et al, Interleukin-6 and tumor necrosis factor levels decrease in the
suction blister fluids of psoriatic patients during effective therapy, Dermatology, 1994189(4):359-63;
Wendling D, et al, Combination therapy of anti-CD4 and anti-IL-6 monoclonal antibodies in a case of
severe spondylarthropathy, Br J Rheumatol., 1996 Dec;35(12):1330; Gratacos J, et al, Serum cytokines
(IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between
serum IL-6 and disease activity and severity, Br J Rheumatol., 1994 Oct;33(10):927-31; Ito H.,
Treatment of Crohn's disease with anti-IL-6 receptor antibody, J Gastroenterol., 2005 Mar;40 Suppl
16:32-4; Ito H, et al, A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal
antibody in active Crohn's disease, Gastroenterology, 2004 Apr;126(4):989-96; discussion 947; Ito H.,
IL-6 and Crohn's disease, Curr Drug Targets Inflamm Allergy, 2003 Jun;2(2):125 Ito H, et al, Anti-IL-6
receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine
model of Crohn's disease, J Gastroenterol., 2002 Nov;37 Suppl 14:56-61; Ito H., Anti-interleukin-6
therapy for Crohn's disease, Curr Pharm Des., 20039(4):295-305; Salvarani C, et al, Acute-phase
reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective follow-up study,
Arthritis Rheum., 2005 Feb 1553(1):33-8; Roche NE, et al, Correlation of interleukin-6 production and
disease activity in polymyalgia rheumatica and giant cell arteritis, Arthritis Rheum., 1993
Sep;36(9):1286-94; Gupta M, et al, Cytokine modulation with immune gamma-globulin in peripheral blood
of normal children and its implications in Kawasaki disease treatment, J Clin Immunol., 2001
May;21(3):193-9; Noris M, et al, Interleukin-6 and RANTES in Takayasu arteritis: a guide for
therapeutic decisions?, Circulation, 1999 Jul 6100(1):55-60; Besbas N, et al, The role of cytokines in
Henoch Schonlein purpura, Scand J Rheumatol., 199726(6):456-60; Hirohata S, et al, Cerebrospinal fluid
interleukin-6 in progressive Neuro-Behcet's syndrome, Clin Immunol Immunopathol., 1997 Jan;82(1):12-7;
Yamakawa Y, et al, Interleukin-6 (IL-6) in patients with Behcet's disease, J Dermatol Sci., 1996
Mar;11(3):189-95; Kim DS., Serum interleukin-6 in Kawasaki disease, Yonsei Med J., 1992 Jun;33(2):183-
- 124 -